Branchburg, NJ (PRWEB) November 29, 2012
Aterovax SA, a private French diagnostics company focused on the development and commercialization of novel cardiovascular diagnostics and ZEUS Scientific, a United States based global in vitro diagnostics company, announced the establishment of an strategic alliance covering Aterovax's patented new biomarker Secreted Phospholipase A2 (sPLA2) for assessment of cardiac risk. Aterovax will supply proprietary reagents to ZEUS Scientific to manufacture and market exclusively an ELISA format sPLA2 test for in vitro diagnostic use in North America and selected European and Latin America countries. Financial terms of the agreement were not disclosed.
sPLA2 is a novel biomarker that helps physicians independently over and above traditional risk markers and risk scores, for :
- Risk stratification in acute coronary syndrome management,
- Prediction of adverse outcomes in patients with stable CHD, and
- Cardiovascular risk assessment in apparently healthy patients
“ZEUS Scientific is excited to execute this agreement with Aterovax”, noted Scott Tourville, CEO of ZEUS Scientific. “This represents ZEUS’ continued investment and expansion in ELISA based laboratory tests. In addition, this represents ZEUS Scientific’s expansion into the diagnostics of cardiovascular disease with a novel biomarker that has very strong scientific data supporting its clinical utility”. Both ZEUS and Aterovax plan to CE mark this ELISA test and ZEUS plans to submit to the USFDA in 2013.
About ZEUS Scientific :
ZEUS Scientific has over 35 years of experience in developing, manufacturing and marketing in vitro diagnostic laboratory tests. No other company offers the breadth and depth of products across both autoimmune disease and infectious serology testing, across three methodologies: IFA, ELISA and multiplex (AtheNA Multi-Lyte). ZEUS Scientific is based in Branchburg, New Jersey and markets test systems around the globe through an extensive distribution network. ZEUS Scientific complies with international standard ISO 13485 (2003), Health Canada Medical Device Regulations (SOR/98-282, May 7 1998), the FDA Quality System Regulations (FDA Quality System Regulation, 1996: 21 CFR § 820) and the IVD 98/79/EEC. For more information visit: http://www.zeusscientific.com
About Aterovax :
Aterovax is developing innovative diagnostic products for the cardiovascular disease market based on a unique understanding of atherosclerosis, the condition responsible for most cardiovascular problems.
Aterovax is currently investigating the role of additional new biomarkers involved in atherosclerosis.
The Company, stemming from the French academic research, was founded in Paris, France in 2006 with financing from the SEFTI fund.
This specialist European cardiovascular fund has been joined by two new partners in 2012, FA DIESE and Turenne Capital Partenaires.
For information about Aterovax please contact Dr Gérald ULRICH at gulrich(at)aterovax(dot)com.
About SEFTI :
SEFTI (Specialized European Fund for Therapeutic Innovation) is a venture capital fund dedicated to early stage investments in French and European private companies, developing biotechnological, pharmaceutical, diagnostics and medical device products. Mainly stemming from the academic research, the fund portfolio’s companies develop innovative projects, covering unmet medical needs that quickly enter into a clinical development phase.
About FA DIESE :
FA DIESE is a Paris-based Angel Fund, with 16M€ under management dedicated to invest in seed and early-stage companies with high growth potential.
Alongside business angels, well known institutional investors such as France Investissement, SCOR and AVIVA came up to enhance the investment capacity of the fund.
Since its foundation in 2007, Fa Dièse has invested more than 60% of its capital into 23 start-ups in the fields of Internet, IT, Life Sciences and industrial technologies.